Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3340186

CNC(=O)c1cccc(-c2ccc(CNC3CCC(C)(C)CC3)cc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.46
PRKD1 Q15139 6/20 0.44
SLC2A1 P11166 3/20 0.43
PDK2 Q15119 1/20 0.42
CRBN Q96SW2 1/20 0.42
MEN1 O00255 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
HTR5A P47898 1/20 0.42
EPHX2 P34913 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
PRKD3 O94806 1/20 0.40
PRKD2 Q9BZL6 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651075 0.93 PRKD1 (0.49) HDAC1PRKD1CRBNMEN1RAB9A
Trifluoroacetic Acid SCHEMBL3341197 0.91 EPHX2 (0.52) HDAC1PRKD1SLC2A1MEN1RAB9A
Trifluoroacetic Acid SCHEMBL3338278 0.89 OPRM1 (0.50) HDAC1PRKD1SLC2A1PDK2MEN1
Trifluoroacetic Acid SCHEMBL3340179 0.88 HTR5A (0.45) HDAC1PRKD1SLC2A1RAB9AHTR5A
Trifluoroacetic Acid SCHEMBL3340242 0.87 HTR5A (0.46) HDAC1SLC2A1RAB9AHTR5AEPHX2
Trifluoroacetic Acid SCHEMBL3340372 0.86 OPRM1 (0.44) HDAC1PRKD1SLC2A1RAB9AHTR5A
SCHEMBL12651503 0.84 EPHX2 (0.58) HDAC1PRKD1MEN1RAB9AKMT2A
Trifluoroacetic Acid SCHEMBL1789142 0.83 SLC2A1 (0.43) HDAC1SLC2A1MEN1RAB9AKMT2A
Trifluoroacetic Acid SCHEMBL16194671 0.83 PRKD1 (0.43) HDAC1PRKD1SLC2A1MEN1RAB9A
Trifluoroacetic Acid SCHEMBL3340025 0.82 OPRM1 (0.47) OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 HDAC1 1478/4885PRKD1 2867/4885SLC2A1 2287/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 HDAC1 2440/4885PRKD1 3367/4885SLC2A1 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.